Severe early-childhood-onset retinal dystrophy
MONDO:0009549Severe early childhood onset retinal dystrophy (SECORD) is an inherited retinal dystrophy, characterized by a severe congenital night blindness, progressive retinal dystrophy and nystagmus. Best corrected visual acuity can reach 0.3 in the first decade of life and can pertain well into the second decade of life. Blindness is often complete by the age of 30 years. An overlap with Leber congenital amaurosis (LCA) occurs when patients are characterized by their visual acuity and panretinal dystrophy.
Also known as: EOSRD, SECORD, Stargardt disease type 1, early-onset severe retinal dystrophy, STGD1, Stargardt disease 1, Stgd, fundus flavimaculatus
37 clinical trials for this condition and its sub-types, 10 tagged with Severe early-childhood-onset retinal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Gene therapy injection aims to save sight in rare eye disease
Disease control Recruiting nowThis early-phase trial tests a new gene therapy called VG801 for Stargardt disease, a genetic condition that causes vision loss. Fifteen people aged 6 and older will receive a single injection under the retina. The main goal is to check safety, but researchers will also measure a…
Phase 1/2 • Sponsor: VeonGen Therapeutics GmbH • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene therapy injection aims to halt blinding eye disease
Disease control Recruiting nowThis early study tests a new gene therapy called ACDN-01 for people with Stargardt disease, a genetic condition that leads to progressive vision loss. The therapy is given as a one-time injection under the retina. The main goals are to check safety and find the right dose, with a…
Phase 1/2 • Sponsor: Ascidian Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New study seeks volunteers for future eye disease treatment
Knowledge-focused Recruiting nowThis prescreening study aims to identify up to 50 people with ABCA4-related retinopathy, including Stargardt disease, for possible participation in future ACDN-01 clinical trials. Participants will undergo genetic testing and various eye exams to confirm their condition. This is …
Sponsor: Ascidian Therapeutics, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New study aims to map how stargardt disease worsens over time
Knowledge-focused Recruiting nowThis observational study will follow 75 people aged 12 to 65 with Stargardt disease type 1, a genetic eye condition that causes vision loss. Researchers will use eye exams and imaging to track how the disease changes over time. The goal is to better understand the disease's progr…
Sponsor: Splice Bio • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:54 UTC